Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for cardiovascular disease
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cardiovascular disease or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on cardiovascular disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Risk of death after first admission for cardiovasculardiseases by country of birth in The Netherlands: a nationwide record-linked retrospective cohort study 19164329 2009 04 15 2009 05 12 2014 07 30 1468-201X 95 9 2009 May Heart (British Cardiac Society) Heart Risk of death after first admission for cardiovasculardiseases by country of birth in The Netherlands: a nationwide record-linked retrospective cohort study. 747-53 10.1136/hrt.2008.159285 To examine differences in short- (28 days (...) ) and long-term (5 years) risk of death in patients hospitalised for the first time for various cardiovasculardiseases (CVD) by country of birth and/or parental country of birth. A nationwide prospective cohort of CVD patients. Entire Netherlands. 118 691 patients hospitalised for the first time for various CVDs were identified through the national hospital discharge, the Dutch population and the cause-of-death registers. Differences in short-term and long-term risk of death. Cox proportional hazard
Cardiovasculardisease. In: Menopause and osteoporosis update 2009. Cardiovasculardisease. In: Menopause and osteoporosis update 2009. | National Guideline Clearinghouse Search Sign In Username or Email * Password * Remember Me Don't have an account? Guideline Summary NGC:006971 This guideline summary has been withdrawn from NGC. Please update your bookmarks. View all withdrawn summaries in the . About NGC Guideline Summaries NGC's guidelines summaries contain information systematically
Summaries for patients. Aspirin for the prevention of cardiovasculardisease: U.S. Preventive Services Task Force recommendation statement. Summaries for patients. Aspirin f... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 2009 ) Volume: 150 , Issue: 6 , Pages: I-37 PubMed: Available from or Find this paper at: Abstract Background: Intravenous sodium bicarbonate has been proposed
Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: a report from the Women`s Ischemia Syndrome Evaluation Study and the St James Women Take Heart Project 19433695 2009 05 12 2009 06 05 2016 12 03 1538-3679 169 9 2009 May 11 Archives of internal medicine Arch. Intern. Med. Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: a report from the Women's Ischemia Syndrome Evaluation Study and the St James Women Take Heart Project (...) women with no history of heart disease who were followed up for 10 years. We compared cardiovascular events (ie, myocardial infarction, stroke, and hospitalization for heart failure) and death in 540 WISE women with suspected ischemia but no angiographic evidence of obstructive CAD with those from a cohort of 1000 age- and race-matched WTH women. Compared with the WISE women, asymptomatic WTH women had a lower prevalence of obesity, family history of CAD, hypertension, and diabetes mellitus (P
Prevalence of cardiovasculardisease risk factors among National Football League players. CONTEXT: Concern exists about the cardiovascular health implications of large size among professional football players and those players who aspire to professional status. OBJECTIVES: To assess cardiovasculardisease (CVD) risk factors in active National Football League (NFL) players and to compare these findings with data from the Coronary Artery Risk Development in Young Adults (CARDIA) study. DESIGN
Plasma asymmetric dimethylarginine and incidence of cardiovasculardisease and death in the community 19289633 2009 03 31 2009 04 24 2016 12 03 1524-4539 119 12 2009 Mar 31 Circulation Circulation Plasma asymmetric dimethylarginine and incidence of cardiovasculardisease and death in the community. 1592-600 10.1161/CIRCULATIONAHA.108.838268 Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, induces endothelial dysfunction. Although elevated ADMA has been (...) associated with an increased risk of cardiovasculardisease events and death in referral samples, the prognostic significance of ADMA in the community has not been adequately evaluated. We related plasma ADMA, l-arginine (Arg), and the ratio of Arg to ADMA to the incidence of cardiovasculardisease (fatal or nonfatal myocardial infarction, coronary insufficiency, angina pectoris, stroke or transient ischemic attack, intermittent claudication, or heart failure) and death in 3320 Framingham Offspring Study
Effect of a pharmacist on adverse drug events and medication errors in outpatients with cardiovasculardisease 19398687 2009 04 28 2009 05 19 2016 10 19 1538-3679 169 8 2009 Apr 27 Archives of internal medicine Arch. Intern. Med. Effect of a pharmacist on adverse drug events and medication errors in outpatients with cardiovasculardisease. 757-63 10.1001/archinternmed.2009.59 Adverse drug events and medication errors are threats to quality care. Inpatient studies suggest that a pharmacist may (...) ), including a lower risk of adverse drug events (risk ratio, 0.65; 95% CI, 0.47-0.90), preventable adverse drug events (risk ratio, 0.52; 95% CI, 0.25-1.09), potential adverse drug events (risk ratio, 0.70; 95% CI, 0.40-1.22), and medication errors (risk ratio, 0.63; 95% CI, 0.40-0.98). This post hoc analysis suggests that pharmacist intervention to improve medication use in outpatients with cardiovasculardisease decreases the risk of adverse drug events and medication errors. Further studies are needed
Differences in control of cardiovasculardisease and diabetes by race, ethnicity, and education: U.S. trends from 1999 to 2006 and effects of medicare coverage. BACKGROUND: Efforts to improve the care of cardiovasculardisease and diabetes or expand insurance coverage for adults with these conditions may reduce differences in clinical outcomes. OBJECTIVE: To assess recent national trends in disease control, trends in sociodemographic differences in control, and changes in sociodemographic (...) in difference, 0.7%; P = 0.005), as were Hispanic-white differences (reduction in difference, 0.7%; P = 0.007) and differences between less and more educated adults (reduction in difference, 0.5%; P = 0.033). LIMITATION: Data were cross-sectional, and estimates may have been biased by coincidental events at age 65 years, such as retirement, that may affect disease control. CONCLUSION: Control of blood pressure and glucose and cholesterol levels has improved since 1999 for adults with cardiovasculardisease
Plasma leptin levels and incidence of heart failure, cardiovasculardisease and total mortality in the elderly 19114611 2009 04 01 2009 07 29 2016 12 03 1935-5548 32 4 2009 Apr Diabetes care Diabetes Care Plasma leptin levels and incidence of heart failure, cardiovasculardisease, and total mortality in elderly individuals. 612-6 10.2337/dc08-1596 Obesity predisposes individuals to congestive heart failure (CHF) and cardiovasculardisease (CVD). Leptin regulates energy homeostasis, is elevated (...) Clin Endocrinol Metab. 1997 Feb;82(2):579-84 9024258 Diabetes Care. 1998 May;21(5):782-6 9589240 Science. 1998 Sep 11;281(5383):1683-6 9733517 Eur Heart J. 1998 Oct;19(10):1547-51 9820994 FASEB J. 1999 Jul;13(10):1231-8 10385613 Am J Public Health Nations Health. 1951 Mar;41(3):279-81 14819398 Am J Epidemiol. 2005 Dec 15;162(12):1189-97 16236994 Lancet. 1983 Mar 5;1(8323):492-5 6131209 Aged Aged, 80 and over Blood Pressure Body Mass Index CardiovascularDiseases blood epidemiology mortality
Performance of the UKPDS Risk Engine and the Framingham risk equations in estimating cardiovasculardisease in the EPIC-Norfolk cohort 19114615 2009 04 01 2009 07 29 2016 11 25 1935-5548 32 4 2009 Apr Diabetes care Diabetes Care Performance of the UK Prospective Diabetes Study Risk Engine and the Framingham Risk Equations in Estimating CardiovascularDisease in the EPIC- Norfolk Cohort. 708-13 10.2337/dc08-1918 The purpose of this study was to examine the performance of the UK Prospective (...) Diabetes Study (UKPDS) Risk Engine (version 3) and the Framingham risk equations (2008) in estimating cardiovasculardisease (CVD) incidence in three populations: 1) individuals with known diabetes; 2) individuals with nondiabetic hyperglycemia, defined as A1C >or=6.0%; and 3) individuals with normoglycemia defined as A1C <6.0%. This was a population-based prospective cohort (European Prospective Investigation of Cancer-Norfolk). Participants aged 40-79 years recruited from U.K. general practices
Aspirin for the prevention of cardiovasculardisease: U.S. Preventive Services Task Force recommendation statement. DESCRIPTION: Update of the 2002 U.S. Preventive Services Task Force (USPSTF) recommendation about the use of aspirin for the prevention of coronary heart disease. METHODS: Review of the literature since 2002, focusing on new evidence on the benefits and harms of aspirin for the primary prevention of cardiovasculardisease, including myocardial infarction and stroke. The new (...) is insufficient to assess the balance of benefits and harms of aspirin for cardiovasculardisease prevention in men and women 80 years or older. (I statement) Do not encourage aspirin use for cardiovasculardisease prevention in women younger than 55 years and in men younger than 45 years. (D recommendation).
Cardiovasculardiseases, diabetes mellitus, and cancer in the occupied Palestinian territory. Heart disease, cerebrovascular disease, and cancer are the major causes of morbidity and mortality in the occupied Palestinian territory, resulting in a high direct cost of care, high indirect cost in loss of production, and much societal stress. The rates of the classic risk factors for atherosclerotic disease-namely, hypertension, diabetes mellitus, tobacco smoking, and dyslipidaemia-are high (...) to this epidemic is inadequate. A large proportion of health-care expenditure is on expensive curative care outside the area. Effective comprehensive prevention programmes should be implemented, and the health-care system should be redesigned to address these diseases.
Erectile dysfunction and cardiovasculardisease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions 19181648 2009 02 02 2009 03 03 2017 02 20 1942-5546 84 2 2009 Feb Mayo Clinic proceedings Mayo Clin. Proc. Erectile dysfunction and cardiovasculardisease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions. 139-48 10.1016/S0025-6196(11)60822-7 Risk factors for cardiovasculardisease and erectile dysfunction (ED) are similar (...) 21;43(2):179-84 14736434 Antihypertensive Agents therapeutic use CardiovascularDiseases epidemiology Comorbidity Diabetes Mellitus epidemiology Dyslipidemias epidemiology Endothelium, Vascular physiopathology Erectile Dysfunction drug therapy epidemiology physiopathology Humans Hypertension drug therapy epidemiology Male Phosphodiesterase Inhibitors therapeutic use Risk Factors 89 PMC2664585 2009 2 3 9 0 2009 2 3 9 0 2009 3 4 9 0 ppublish 19181648 S0025-6196(11)60822-7 10.1016/S0025-6196(11)60822-7
Leptin predicts diabetes but not cardiovasculardisease: results from a large prospective study in an elderly population 19001191 2009 01 27 2009 03 11 2015 11 19 1935-5548 32 2 2009 Feb Diabetes care Diabetes Care Leptin predicts diabetes but not cardiovasculardisease: results from a large prospective study in an elderly population. 308-10 10.2337/dc08-1458 To clarify the association of circulating levels of leptin with risk for cardiovasculardisease (CVD) events and new-onset diabetes (...) Jan;22(1):65-70 10333905 Lancet. 2008 Jun 7;371(9628):1927-35 18501419 Blood Press. 2004;13(4):243-6 15581339 Atherosclerosis. 2006 Nov;189(1):47-60 16580676 Diabetes Care. 2007 May;30(5):1200-5 17322479 Diabetologia. 2007 Jun;50(6):1178-85 17372717 Int J Obes (Lond). 2007 Jul;31(7):1126-33 17325688 Obesity (Silver Spring). 2007 Jul;15(7):1694-701 17636087 J Am Coll Cardiol. 2004 Nov 2;44(9):1819-24 15519013 Aged Aged, 80 and over Biomarkers blood CardiovascularDiseases epidemiology Diabetes
Comparison of prognosis for men with type 2 diabetes mellitus and men with cardiovasculardisease 19124789 2009 01 06 2009 01 27 2014 09 01 1488-2329 180 1 2009 Jan 06 CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne CMAJ Comparison of prognosis for men with type 2 diabetes mellitus and men with cardiovasculardisease. 40-7 10.1503/cmaj.071027 People with type 2 diabetes mellitus are at high risk for cardiovasculardisease. In some studies (...) , the mortality rate among people with this condition has been equivalent to that among people with cardiovasculardisease. We compared cardiovascular mortality between incident cases of diabetes and cardiovasculardisease. The study population was part of a random sample of 4376 men from Quebec, Canada, aged 35 to 64 years, who did not have cardiovasculardisease in 1974 and who were followed until 1998. Three groups of incident cases were identified: diabetes without cardiovasculardisease, first
Should the first priority in cardiovascular risk management be those with prior cardiovasculardisease? 18381374 2008 12 25 2009 03 27 2009 09 25 1468-201X 95 2 2009 Feb Heart (British Cardiac Society) Heart Should the first priority in cardiovascular risk management be those with prior cardiovasculardisease? 125-9 10.1136/hrt.2007.140905 Cardiovasculardisease (CVD) prevention guidelines typically dichotomise patients by history of CVD, as patients with prior CVD are assumed to be at high CVD (...) Zealand. email@example.com Broad J J Wells S S Riddell T T Jackson R R eng Journal Article Multicenter Study Research Support, Non-U.S. Gov't 2008 04 01 England Heart 9602087 1355-6037 AIM IM Ann Intern Med. 2009 May 19;150(10):JC5-15 19451571 Evid Based Med. 2009 Aug;14(4):122 19648438 Evid Based Nurs. 2009 Oct;12(4):123 19779090 Heart. 2009 May;95(10):783-4 19131441 Adult CardiovascularDiseases complications epidemiology therapy Epidemiologic Methods Female Guideline Adherence Humans Male
Cardiovasculardisease risk prediction with and without knowledge of genetic variation at chromosome 9p21.3. BACKGROUND: Although genetic variation at chromosome 9p21.3 is associated with incident cardiovasculardisease, it is unclear whether screening for this polymorphism improves risk prediction. OBJECTIVE: To determine whether knowledge of variation at chromosome 9p21.3 provides predictive information beyond that from other readily available risk factors. DESIGN: Prospective cohort study (...) . SETTING: United States. PATIENTS: 22 129 female white health professionals participating in the Women's Genome Health Study, initially without any major chronic disease, who were prospectively followed over a median of 10.2 years for incident cardiovasculardisease. MEASUREMENTS: Polymorphism at rs10757274 in chromosome 9p21.3 and additional cardiovasculardisease risk factors (blood pressure, smoking status, diabetes, blood levels of cholesterol, high-sensitivity C-reactive protein, and family
Prevention of cardiovasculardisease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials Prevention of cardiovasculardisease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials Prevention of cardiovasculardisease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials Mannucci E, Monami M, Lamanna C, Gori F, Marchionni N CRD summary This review found intensive glycaemic control (...) therapy in patients with type 2 diabetes reduced the risk of cardiovascular events and myocardial infarction, but not the incidence of stroke, heart failure and mortality; it increased weight gain and the risk of hypoglycaemia. Potential bias in the review and variation between trials mean that the authors' conclusions should be treated with caution. Authors' objectives To assess the effects of treatment to improve glycaemic control on the incidence of cardiovasculardiseases in patients